<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715998</url>
  </required_header>
  <id_info>
    <org_study_id>QGC001-2QG4</org_study_id>
    <nct_id>NCT03715998</nct_id>
  </id_info>
  <brief_title>Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction</brief_title>
  <acronym>QUORUM</acronym>
  <official_title>A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quantum Genomics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quantum Genomics SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2
      study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily
      doses) versus ramipril administered orally BID over 12 weeks after acute anterior MI.

      Subjects will be followed for 12 weeks (over 4 study visits). A total of 294 male and female
      subjects with a diagnosis of first acute anterior MI will be randomized. The subjects will
      need to have a primary percutaneous coronary intervention (PCI) of the index MI related
      artery within 24 hours after MI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At Inclusion Visit (Visit 2 [within 72 hours after acute MI]), subjects will be randomly
      assigned to 1 of the following 3 treatment groups in a 1:1:1 ratio:

        -  Group 1: Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for
           10 weeks

        -  Group 2: Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for
           10 weeks

        -  Group 3: Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10
           weeks

      Then subjects will undergo study procedures at Titration Visit (Visit 3 [Day 14]), Treatment
      Visit (Visit 4 Day 42]) and End-of-Treatment Visit (Visit 5 [Day 84]).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction assessed by cardiac magnetic resonance imaging (CMRI)</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID oral administration of 2 doses of firibastat to those of BID oral administration of ramipril on the change from Baseline in LVEF on Day 84</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left-ventricle end-diastolic volume assessed by CMRI</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on the change from Baseline to Day 84 in left-ventricle end-diastolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left-ventricle end-systolic volume assessed by CMRI</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on the change from Baseline to Day 84 in left-ventricle end-systolic volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiac event (MACE): combined clinical endpoint of cardiovascular death, MI, and cardiac hospitalization</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on major cardiac event (MACE) over 84 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro b-type natriuretic peptide (NT proBNP)</measure>
    <time_frame>84 days</time_frame>
    <description>Comparison of the effects of BID administration of firibastat and ramipril on the change from Baseline to Day 84 in N-terminal pro b-type natriuretic peptide (NT proBNP)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Group 1: firibastat 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: firibastat 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: ramipril 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>1 or 2 capsules administered orally, twice daily</description>
    <arm_group_label>Group 3: ramipril 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firibastat</intervention_name>
    <description>1 or 2 capsules administered orally, twice daily</description>
    <arm_group_label>Group 1: firibastat 50 mg</arm_group_label>
    <arm_group_label>Group 2: firibastat 250 mg</arm_group_label>
    <other_name>QGC001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of first acute anterior MI (ST-elevation myocardial infarction) defined as
             chest pain &gt;30 minutes and ST elevation ≥0.2 mV in at least 2 consecutive
             electrocardiogram (ECG) leads in the anterior area (DI, aVL, V1 V6).

          -  Primary PCI of the index-MI-related artery within 24 hours after the MI.

        Exclusion Criteria:

          -  Body mass index &gt;45 kg/m².

          -  Subject is hemodynamically unstable or has cardiogenic shock.

          -  Subjects with clinical signs of HF (Kilipp III and IV).

          -  Systolic blood pressure &lt;100 mmHg at inclusion visit

          -  Early primary PCI of the index-MI-related artery performed within 3 hours after MI.

          -  Subjects treated with angiotensin-converting-enzyme inhibitor (ACE I), angiotensin
             receptor blocker (ARB) or sacubitril/valsartan prior to the index magnetic resonance
             imaging. Note: if treatment was for HTN, ACE I/ARB should be stopped, and, if
             necessary, another therapeutic class can be prescribed for HTN. If the ACE I/ARB was
             prescribed for congestive HF, the subject is not considered eligible; if the ACE I/ARB
             prescribed for another reason cannot be stopped, the subject is not eligible for study
             inclusion.

          -  Subjects scheduled for implantable cardioverter defibrillator (ICD), cardiac
             resynchronization therapy, or pacemaker within the next 3 months. If an ICD is
             indicated for ventricular arrhythmia during the course of the study, a life vest, when
             possible, should be prescribed and the ICD scheduled after study completion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Montalescot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière - Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Besse, MD</last_name>
    <phone>+33 1 85 34 77 70</phone>
    <email>bruno.besse@quantum-genomics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Desbrandes, PharmD</last_name>
    <phone>+33 1 85 34 77 70</phone>
    <email>stephanie.desbrandes@quantum-genomics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpêtrière - Institut de Cardiologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Montalescot</last_name>
      <phone>+33 1 42 16 29 59</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

